Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis (Q44409439)

2 December 2017

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis (English)

1 reference

2 December 2017

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

25 December 2023

8

Claus Bachert

1 reference

2 December 2017

4

Marek L Kowalski

1 reference

2 December 2017

1

Ulrich Wahn

1 reference

2 December 2017

6

Gunilla Hedlin

1 reference

2 December 2017

Carlos E Baena-Cagnani

10

object named as

Carlos Baena-Cagnani

1 reference

2 December 2017

12

F. Estelle R. Simons

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704355

25 December 2023

author name string

Paola Decosta

5

1 reference

2 December 2017

Pierre Scheinmann

7

1 reference

2 December 2017

Paul Potter

11

1 reference

2 December 2017

Erik Ruuth

13

1 reference

2 December 2017

Eli O. Meltzer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704355

25 December 2023

Albert F. Finn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704355

25 December 2023

Jose E. Rosado Pinto

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704355

25 December 2023

Carlos Baena-Cagnani

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704355

25 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

full work available at URL

2 December 2017

http://www.jacionline.org/article/S0091674903008467/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704355

https://api.elsevier.com/content/article/PII:S0091674903008467?httpAccept=text/xml

25 December 2023

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

https://api.elsevier.com/content/article/PII:S0091674903008467?httpAccept=text/plain

25 December 2023

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

The Journal of Allergy and Clinical Immunology

25 December 2023

published in

1 reference

2 December 2017

111

1 reference

2 December 2017

4

1 reference

2 December 2017

763-769

1 reference

H1-antihistamines in children

2 December 2017

1

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee

25 December 2023

2

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

An overview of current pharmacotherapy in perennial rhinitis

25 December 2023

3

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

A cost of illness study of allergic rhinitis in the United States

25 December 2023

4

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Epidemiologic evidence for asthma and rhinitis comorbidity.

25 December 2023

6

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Complications of allergic rhinitis.

25 December 2023

7

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Quality of life in adults and children with allergic rhinitis

25 December 2023

8

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids

25 December 2023

9

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Control of Allergic Rhinitis with Antihistamines May Prevent the Onset or Recurrence of Otitis Media

25 December 2023

10

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

The role of nasal airway obstruction in sinus disease and facial development

25 December 2023

11

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Learning impairment and allergic rhinitis.

25 December 2023

12

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study

25 December 2023

13

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity

25 December 2023

14

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years

25 December 2023

16

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Loratadine-pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial

25 December 2023

18

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age

25 December 2023

19

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis

25 December 2023

20

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

25 December 2023

21

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

25 December 2023

22

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

The clinical pharmacology of fexofenadine in children

25 December 2023

24

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Safety of fexofenadine in children treated for seasonal allergic rhinitis

25 December 2023

25

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Allergic rhinitis and its impact on asthma

25 December 2023

26

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma

25 December 2023

27

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma

25 December 2023

28

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up

25 December 2023

30

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Nasal patency in children with allergic rhinitis: correlation of objective and subjective assessments

25 December 2023

32

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

25 December 2023

33

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis

25 December 2023

34

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Histamine-induced activation of human lung macrophages

25 December 2023

35

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines.

25 December 2023

36

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast

25 December 2023

37

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.

25 December 2023

38

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

The systemic safety of fexofenadine HCl.

25 December 2023

39

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers

25 December 2023

41

1 reference

https://api.crossref.org/works/10.1067/MAI.2003.1384

25 December 2023

Identifiers

1 reference

2 December 2017

1 reference